149 related articles for article (PubMed ID: 37022170)
1.
Gill CM; Nicolau DP
Antimicrob Agents Chemother; 2023 May; 67(5):e0173822. PubMed ID: 37022170
[TBL] [Abstract][Full Text] [Related]
2.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987156
[TBL] [Abstract][Full Text] [Related]
3.
Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
[TBL] [Abstract][Full Text] [Related]
4. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Gill CM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
Nicasio AM; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2009 Jul; 53(7):2756-61. PubMed ID: 19364850
[TBL] [Abstract][Full Text] [Related]
6. Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416551
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models.
van der Meijden A; Aranzana-Climent V; van der Spek H; de Winter BCM; Couet W; Meletiadis J; Muller AE; van den Berg S
J Antimicrob Chemother; 2023 Mar; 78(3):832-839. PubMed ID: 36718051
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin pharmacodynamics against Stenotrophomonas maltophilia in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision.
Fratoni AJ; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2021 Dec; 77(1):164-168. PubMed ID: 34542637
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
Andes D; Craig WA
Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
[TBL] [Abstract][Full Text] [Related]
11.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models.
Landersdorfer CB; Wang J; Wirth V; Chen K; Kaye KS; Tsuji BT; Li J; Nation RL
J Antimicrob Chemother; 2018 Feb; 73(2):462-468. PubMed ID: 29149294
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Evaluation of MRX-8, a Novel Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative Pathogens.
Lepak AJ; Wang W; Andes DR
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868332
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
Andes D; Craig WA
Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
[TBL] [Abstract][Full Text] [Related]
15. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models.
Dudhani RV; Turnidge JD; Nation RL; Li J
J Antimicrob Chemother; 2010 Sep; 65(9):1984-90. PubMed ID: 20573659
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Crandon JL; Banevicius MA; Nicolau DP
Antimicrob Agents Chemother; 2009 Mar; 53(3):1165-9. PubMed ID: 19114676
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
Dudhani RV; Turnidge JD; Coulthard K; Milne RW; Rayner CR; Li J; Nation RL
Antimicrob Agents Chemother; 2010 Mar; 54(3):1117-24. PubMed ID: 20028824
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints.
Abbott IJ; Mouton JW; Peleg AY; Meletiadis J
J Antimicrob Chemother; 2021 Nov; 76(12):3201-3211. PubMed ID: 34473271
[TBL] [Abstract][Full Text] [Related]
20.
Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
